Abstract:Background and objectives: This study aimed to investigate the clinical, radiological, pathological features, treatment options, and outcomes of isocitrate dehydrogenase (IDH)-mutant brainstem gliomas (BSG-IDH mut ). Methods: A retrospective analysis of 22 patients diagnosed with BSG-IDH mut and treated at our institution from January 2011 to January 2017 was performed. Their clinical, radiological data, and long-term outcomes were collected and analyzed. Results: The median age of patients was 38.5 years, with a male predominance (63.6%). All patients had IDH1 and TP53 mutations, with noncanonical IDH mutations in 59.1% of cases, 06-methylguanine-DNA methyltransferase promoter methylation in 55.6%, and alpha-thalassemia mental retardation X-linked loss in 63.2%, respectively. Tumors were primarily located in the pontine-medullary oblongata (54.5%) and frequently involved the pontine brachium (50%). Most tumors exhibited ill-defined boundaries (68.2%), no T2-FLAIR mismatch (100%), and no contrast enhancement (86.3%). Two radiological growth patterns were also identified: focal and extensively infiltrative, which were associated with the treatment strategy when tumor recurred. Seven patients (31.8%) received surgery only and 15 (68.2%) surgery plus other therapy. The median overall survival was 124.8 months, with 1-year, 2-year, 5-year, and 10-year survival rates of 81.8%, 68.2%, 54.5%, and 13.6%, respectively. Six patients experienced tumor recurrence, and all retained their radiological growth patterns, with 2 transformed into central nervous system World Health Organization grade 4. Conclusion: BSG-IDH mut represents a unique subgroup of brainstem gliomas with distinctive features and more favorable prognosis compared with other brainstem gliomas. Further research is required to better understand the molecular mechanisms and optimize treatment strategies for this rare and complex disease.

Therapies for IDH-Mutant Gliomas

Targeting IDH-Mutant Glioma

Advances in the treatment of IDH-mutant gliomas

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

Treatment Options for IDH-Mutant Malignant Gliomas

Treatment of IDH-mutant glioma in the INDIGO era

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

The Role of Mutant IDH Inhibitors in the Treatment of Glioma

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review

IDH inhibition in gliomas: from preclinical models to clinical trials

Brainstem Gliomas With Isocitrate Dehydrogenase Mutation: Natural History, Clinical-Radiological Features, Management Strategy, and Long-Term Outcome